1. Safety of biweekly α 1 -antitrypsin treatment in the RAPID programme.
- Author
-
Greulich T, Chlumsky J, Wencker M, Vit O, Fries M, Chung T, Shebl A, Vogelmeier C, Chapman KR, and McElvaney NG
- Subjects
- Adult, Female, Humans, Infusions, Intravenous, Lung physiopathology, Male, Middle Aged, Pulmonary Emphysema etiology, Pulmonary Emphysema physiopathology, Treatment Outcome, alpha 1-Antitrypsin adverse effects, alpha 1-Antitrypsin Deficiency complications, alpha 1-Antitrypsin Deficiency physiopathology, Pulmonary Emphysema drug therapy, alpha 1-Antitrypsin administration & dosage, alpha 1-Antitrypsin Deficiency drug therapy
- Abstract
Competing Interests: Conflict of interest: T. Greulich reports personal fees from AstraZeneca and GSK (lecture fees), Boehringer-Ingelheim, Chiesi, CSL Behring and Novartis (lecture fees, advisory board and travel support), and Mundipharma (lecture fees and advisory board); and grants and personal fees from Grifols (AATD-Labor, lecture fees and travel support), all outside the submitted work. Conflict of interest: J. Chlumsky reports honoraria for lectures organised by CSL Behring, and for lectures organised by Boehringer Ingelheim, outside the submitted work. Conflict of interest: M. Wencker reports support from conresp as a consultant to CSL Behring, during the conduct of the study. Conflict of interest: O. Vit reports support from CSL Behring, as employer and sponsor of the study. Conflict of interest: M. Fries reports support from CSL Behring, as employer and sponsor of the study. Conflict of interest: T. Chung reports support from CSL Behring, as employer and sponsor of the study. Conflict of interest: A. Shebl reports support from CSL Behring, as employer and sponsor of the study. Conflict of interest: C. Vogelmeier reports grants and personal fees from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Grifols and Novartis; personal fees from CSL Behring, Chiesi, Menarini, Mundipharma, Teva and Cipla; and grants from Bayer-Schering, MSD and Pfizer, all outside the submitted work. Conflict of interest: K.R. Chapman reports grants and personal fees from AstraZeneca, Boehringer Ingelheim, CSL Behring, Grifols, Sanofi, Genentech, Kamada, Roche and Novartis; grants from Baxter, GlaxoSmithKline, Amgen, Shire and Octapharma; personal fees from Merck; and the CIHR-GSK Research Chair in Respiratory Health Care Delivery, UHN, all during the conduct of the study. Conflict of interest: N.G. McElvaney reports research grants for carrying out the original RAPID and RAPID OLE studies from CSL Behring, during the conduct of the study; and personal fees from CSL Behring (advisory board), outside the submitted work.
- Published
- 2018
- Full Text
- View/download PDF